Publications by authors named "P Perini"
Article Synopsis
- The study focuses on pediatric-onset multiple sclerosis (POMS) patients, who often face cognitive issues, and examines how natalizumab (NTZ) affects their cognitive function compared to adult-onset multiple sclerosis (AOMS) patients.
- Involving 63 patients, researchers monitored cognitive performance using the Symbol Digit Modalities Test (SDMT) over at least 24 months, noting significant cognitive improvement in both POMS and AOMS, with POMS showing greater gains.
- Results suggest that natalizumab not only helps manage disease activity but also enhances cognitive function in POMS, making it a promising treatment option for younger patients.
We report the case of a patient suffering from biopsy-proven relapsing tumefactive demyelinating lesions (TDLs) of the central nervous system who had five relapses in 16 years. No signs/symptoms suggestive of alternative pathologies emerged during the follow-up. A limited benefit was observed with intravenous (IV) high-dose steroids, while both plasma exchange and IV immunoglobulin G (IgG) administration were ineffective.
View Article and Find Full Text PDFArticle Synopsis
- The study compares disability progression in Multiple Sclerosis (MS) patients based on age of onset: pediatric (POMS), adult (AOMS), and late-onset (LOMS), as well as those with and without progression independent of relapse activity (PIRA).
- Data from 3,777 MS patients revealed that AOMS showed significant disability increases compared to POMS starting in the second year, with POMS having a less steep disability trajectory over time.
- The findings underscore that younger patients with MS experience different disability progression patterns than older patients, highlighting the importance of age in MS disease management.
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
J Neurol
October 2024
Background: In multiple sclerosis (MS), imaging biomarkers play a crucial role in characterizing the disease at the time of diagnosis. MRI and optical coherence tomography (OCT) provide readily available biomarkers that may help to define the patient's clinical profile. However, the evaluation of cortical and paramagnetic rim lesions (CL, PRL), as well as retinal atrophy, is not routinely performed in clinic.
View Article and Find Full Text PDFHigh NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
September 2024
Background And Objectives: Although pediatric-onset multiple sclerosis (POMS) is characterized by a more rapid accumulation of CNS inflammation than adult-onset MS (AOMS), the therapeutic algorithms applied in POMS are usually based on AOMS therapeutic outcomes. To define a high-efficacy treatment (HET)-based strategy to treat POMS, we designed an observational retrospective study aimed at evaluating the efficacy and safety of natalizumab (NTZ) in naïve POMS and AOMS.
Methods: Starting from 160 patients, we applied a 2:1 (adult:pediatric) matching on propensity scores and obtained 32 patients with NTZ-treated POMS and 64 with AOMS, estimated from a multivariable logistic regression model.